Israel’s Arkin Capital announced on Tuesday that it has closed a $100 million Bio Ventures III fund to invest in advanced pre-clinical and early clinical-stage biotech companies developing therapies for areas of high unmet medical need.
With the launch of its third early-stage fund, Arkin Bio now manages more than $600 million in biotech-focused assets under management across both early- and late-stage strategies, the company said. Institutional investors, including Phoenix and Clal Insurance, back the new fund.
Arkin said Bio Ventures III is expected to invest in up to a dozen companies worldwide, with a focus on oncology, immunology, inflammation, rare diseases, and other high-impact therapeutic areas. “We launched Arkin Bio Ventures III to deepen our commitment to frontline science and the teams bringing it to life,” said Dr. Pini Orbach, managing partner at Arkin Bio.
Founded in 2009, Arkin Capital invests across private equity and venture capital. Beyond healthcare, the firm operates investment arms in equity, technology, and real estate. Its healthcare portfolio includes more than 20 successful exits through IPOs and acquisitions, including UroGen Pharma, Bluejay Therapeutics, Keros Therapeutics, Censa Pharmaceuticals, ImmPACT Bio, cCAM Biotherapeutics, and Hi-Bio.
Arkin Bio Ventures I closed in 2016, followed by the second fund in 2020. The new fund is expected to work closely with founders on biological strategy, translational planning, and clinical positioning, aiming to build companies that can reach meaningful value milestones and attract institutional investors and strategic partners.
The announcement comes as Israel’s health technology sector continues to draw significant investment. According to Startup Nation Central, the health-tech ecosystem raised $1.2 billion in private funding in 2024, with biotech accounting for a substantial share of that total.
“This fund allows us to lean further into advanced pre-clinical opportunities and help accelerate private companies to bring breakthrough technologies to proof-of-concept,” Orbach added. “With our combined scientific expertise, investment discipline, and global network, we’re proud to be a true partner from day one.”